United Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat

Dow Jones

02/26

By Amira McKee

Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year.

The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year.

Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers.

United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027.

Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note.

United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier.

The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet.

Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated.

Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million.

The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 25, 2026 13:25 ET (18:25 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614030678"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614030678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614030678?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 02:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614030678","market":"hk","top_or_hot":-1,"title":"United Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. \n</p>\n<p>\n  The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year. \n</p>\n<p>\n  Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers. \n</p>\n<p>\n  United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027. \n</p>\n<p>\n  Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note. \n</p>\n<p>\n  United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier. \n</p>\n<p>\n  The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet. \n</p>\n<p>\n  Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated. \n</p>\n<p>\n  Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million. \n</p>\n<p>\n  The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 13:25 ET (18:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-26 02:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. \n</p>\n<p>\n  The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year. \n</p>\n<p>\n  Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers. \n</p>\n<p>\n  United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027. \n</p>\n<p>\n  Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note. \n</p>\n<p>\n  United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier. \n</p>\n<p>\n  The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet. \n</p>\n<p>\n  Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated. \n</p>\n<p>\n  Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million. \n</p>\n<p>\n  The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 13:25 ET (18:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美國聯合醫療","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614030678","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614030678","pubTimestamp":1772043900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year.The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year.Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers.United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027.Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note.United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compare","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"United Therapeutics因开发新型吸入器而获利，第四季度净利润超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. \n\n\n  The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year. \n\n\n  Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers. \n\n\n  United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027. \n\n\n  Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note. \n\n\n  United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier. \n\n\n  The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet. \n\n\n  Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated. \n\n\n  Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million. \n\n\n  The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 13:25 ET (18:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}